Table 2.

Change in eGFR slope before and after CS + MPAA treatment

	12 months prior to baseline (n = 25)	From baseline to the last visit with CS + MPAA treatment (n = 25)	From baseline to the last visit with CS + MPAA treatment (n = 21)	From the last visit with CS + MPAA treatment to end of follow-up (n = 21)
	4
eGFR slope (mL/min/1.73 m2/year)	–23 (–32 to –16)	5 (3–9)*	4 (3–8)	–2.1 (–6.4 to –0.6)**, ***

*P = 0.001 and **P = 0.001 compared with the eGFR slope between baseline and the last visit with CS + MPAA treatment and ***P = 0.001 compared with the eGFR slope in the 12 months prior to baseline.